Key Highlights

  • Thermo Fisher Scientific (NYSE:TMO) reports third-quarter results before the open on Wednesday, October 21, 2026, with consensus earnings of USD 6.40 per share, up from USD 5.79, and revenue of USD 11.93 billion.
  • The shares closed the October 19 session at USD 679.38, down 1.54%, about 3.5% below their 52-week high, with a market value of USD 251.2 billion in published market data.
  • Morgan Stanley raised its target to USD 730 from USD 650 and TD Cowen to USD 760 from USD 675 on October 13, both citing improving pharma and biotech demand ahead of the quarter.
  • UBS upgraded the stock to Buy on September 9 with a USD 730 target, up from USD 540, and CLSA started coverage with Outperform and a USD 748 target on September 3.

What the Report Needs to Show

The company is the first among life science tools peers to report this season, so its results set the tone for the group. Consensus expects earnings of USD 6.40 per share and revenue of USD 11.93 billion against USD 11.12 billion a year earlier, or growth of about 7%, a figure that is simple arithmetic on two published numbers. Last quarter revenue was USD 11.99 billion, up 10.5%, with a beat on organic growth. Analysts say the sector is helped by improving demand from pharma and biotech customers. Thermo Fisher Scientific (NYSE:TMO) fell 1.54% on October 19, so the shares enter the report slightly lower. The 52-week high is implied at about USD 704 from the 3.5% gap.

Deals, Rotation and Mechanism

The company sells instruments, consumables, software and services to labs, and its bioprocessing and clinical research units earn recurring revenue when customers run more experiments and manufacture more drugs. The Clario acquisition added digital endpoint data for clinical trials and tracked above expectations in the second quarter. The filtration and separation business bought from Solventum for about USD 4.0 billion in cash is expected to produce USD 125 million of adjusted operating income from synergies by the fifth year after closing. Strategists have also pointed to a rotation out of artificial intelligence names into healthcare, and life science tools have beaten the rest of the sector this year.

Risks and What to Watch

Expectations have risen: shares gained about 2.9% in the past month while targets moved up, so guidance matters more than the quarter. Demand from pharma and biotech funding, academic budgets and China can change quickly, and weaker medical device results from a large peer on October 13 pulled healthcare names lower that day. Integration of acquisitions carries cost and execution risk, and a stronger dollar or tariffs could trim reported margins. Watch organic growth, any change to full-year guidance and commentary on bioprocess orders, and compare them with the Morgan Stanley, TD Cowen and Barclays targets of USD 730, USD 760 and USD 750. Any cut to demand commentary could outweigh a headline beat.

Where Things Stand

The report is scheduled before the open on October 21, and results will tell investors whether improving pharma and biotech demand is showing up in orders and guidance. The balance of evidence is positive, since targets rose and acquisitions are on track, yet the shares are priced for a good quarter. The next catalysts are the results themselves and peer reports. This is not investment advice, and estimates are not guarantees.